Drug Trial Radar · NCT04303507
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,652
Actual
Start
Apr 29, 2020
Primary completion
Mar 22, 2022
Study completion Mar 22, 2022
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 11, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a double-blind, randomised, placebo-controlled trial that will be conducted primarily in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other persons at risk of contracting COVID-19, who can be followed reliably for 5 months. The initial aim was to recruit 40,000 participants and we predict an average of 400-800 participants per site in 50-100 sites. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation), or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10mg base/kg (four 155mg tablets for a 60kg subject), followed by 155 mg daily (250mg chloroquine phosphate salt/ 200mg hydroxychloroquine sulphate) will be taken for 3 months. If the participant is diagnosed with COVID-19, they will take continue to take the study medication until: * 90 days after enrolment (i.e., completion of kit) * hospitalised due to COVID-19 disease (i.e., not for quarantine purposes) in which case they will stop, or * advised to stop by their healthcare professional for other reasons Episodes of symptomatic respiratory illness, including symptomatic COVID-19, and clinical outcomes will be recorded in the Case Record Form during the follow-up period. This study is funded by Wellcome Trust Grant reference 221307/Z/20/Z.
Conditions
- COVID19
- Coronavirus
- Acute Respiratory Illnesses
Interventions
Chloroquine or HydroxychloroquineDrug
A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of symptomatic COVID-19 infectionsTime frame: Approximately 90 days
Locations
25 sites in 10 countries. Site status is shown where the registry gives one.
Centre Hospitalier et Universitaire de Zone Abomey-Calavi
Abomey-Calavi, Benin
Hospital De Zone Allada
Allada, Benin
University Hospital Center of Angre
Abidjan, Côte d’Ivoire
University Hospital Center of Bouake
Bouaké, Côte d’Ivoire
Sardjito Hospital
Yogyakarta, Indonesia
Airlangga University Hospital (UNAIR)
Surabaya, East Java, Indonesia
Husada Utama Hospital
Surabaya, East Java, Indonesia
Bunda Thamrin Hospital
Medan, North Sumatra, Indonesia
Murni Teguh Memorial Hospital
Medan, North Sumatra, Indonesia
Fountain Healthcare Hospital
Eldoret, Kenya
Mbagathi County Hospital
Nairobi, Kenya
The Bamako Hospital of Dermatology
Bamako, Mali
Hospital Of Mali
Bamako, Mali
B.P. Koirala Institute of Health Sciences
Dharān, Nepal
The Aga Khan University Hospital
Karachi, Pakistan
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand
Birmingham & Solihull Mental Health NHS Trust
Birmingham, United Kingdom
Brighton and Sussex University Hospitals NHS Trust
Brighton, United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, United Kingdom
Rotherham, Doncaster And South Humber NHS Foundation Trust
Doncaster, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
Oxford University Hospital NHS Foundation Trust
Oxford, United Kingdom
University Hospitals Of Morecambe Bay NHS Foundation Trust
Kendal, Cumbria, United Kingdom
The Dudley Group NHS Foundation Trust
Dudley, West Midlands, United Kingdom
Zambart
Lusaka, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.